Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIL 284 BS in Patients With Hepatic Impairment
NCT02265627Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2000
- Primary completion
- Sep 2000
01
Overview
Phase 1, open-label trial of amelubant in chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Plasma concentration-time profiles at 84 hours. Started Mar 2000; status: completed.
02
Drugs
amelubant
03
Conditions
chronic obstructive pulmonary disease (COPD)cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02265627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265627.